TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth In Vivo
Scientists provide evidence that tumor suppressor candidate 3 (TUSC3) is part of the oligosaccharyltransferase complex and affects N-linked glycosylation in mammalian cells. Loss of TUSC3 expression in DU145 and PC3 prostate cancer cell lines leads to increased proliferation, migration and invasion as well as accelerated xenograft growth in a PTEN negative background. [Sci Rep]
Full Article
CLINICAL RESEARCH
Genetic Variations in TP53 Binding Sites Are Predictors of Clinical Outcomes in Prostate Cancer Patients
Since the tumor protein p53 (TP53), a transcription factor, plays a crucial role in prostate cancer development and progression, we hypothesized that sequence variants in TP53 binding sites might affect clinical outcomes in patients with prostate cancer. We systematically evaluated 41 single nucleotide polymorphisms within genome-wide predicted TP53 binding sites in a cohort of 1,024 prostate cancer patients. [Arch Toxicol]
Full Article
Statins: Protectors or Pretenders in Prostate Cancer?
The role of statin therapy in prostate cancer (PCa) prevention and treatment is plagued by controversy. This critical review of published clinical series reveals several caveats in earlier studies, which reported no benefit. Recent studies that adjust for confounding factors have demonstrated statin therapy to be associated with PCa prevention and favorable clinical outcomes. [Trends Endocrinol Metab]
Abstract
Emerging Roles of Radioresistance in Prostate Cancer Metastasis and Radiation Therapy
The authors discuss the novel findings of phosphoinositide 3-kinase/Akt/phosphatase and tensin homolog/mammalian target of rapamycin signaling pathway, autophagy, epithelial-mesenchymal transition and cancer stem cells in the regulation of prostate cancer (CaP) metastasis and radioresistance, and focus on combination of radiosensitizers with radiation therapy in the treatment of CaP in preclinical studies to explore novel approaches for future clinical trials. [Cancer Metastasis Rev]
Full Article
Visit our reviews page to see a complete list of reviews in the prostate cell research field.
SCIENCE NEWS
Melatonin May Lower Prostate Cancer Risk
Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may suggest decreased risk for developing advanced prostate cancer, according to results. [Press release from American Association of Cancer Research (AACR) discussing research presented at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, San Diego]
Press Release
Starpharma Commences Dendrimer-Docetaxel Clinical Trial
Starpharma announced that it has received the necessary approvals to commence a Phase I human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel. [Starpharma]
Press Release
The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids
The HUB Foundation for Organoid Technology announced that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation. [STEMCELL Technologies Inc.]
Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Prostate Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.